| Description | Utibapril is an inhibitor of angiotensin-converting enzyme (ACE) with antihypertensive activities. |
| In vivo | Utibapril significantly inhibits plasma, renal, and vascular ACE but not ventricular ACE activity. vascular ACE activity significantly inhibited by Utibapril (2 μg/kg/day), and Utibapril (250 μg/kg/day) results in a significant inhibition of plasma ACE.After treatment with the higher doses of utibapril, Furthermore, angiotensin I-induced decreases in coronary flow in the isolated heart are significantly inhibited [1]. FPL 63547 is rapidly and extensively excreted as the diacid in the bile but appeared in the urine in negligible amounts[2]. |
| Synonyms | FPL 63547 |
| molecular weight | 449.56 |
| Molecular formula | C22H31N3O5S |
| CAS | 109683-61-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Buikema H, et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol. 1997 May;29(5):684-91. 2. Carr RD, et al. Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Br J Pharmacol. 1990 May;100(1):90-4. |